Role of CT and SPECT in the assessment of therapeutic effect of anticoagulation or thrombolytic therapy for pulmonary thromboemboslism

Role of CT and SPECT in the assessment of therapeutic effect of anticoagulation or thrombolytic therapy for pulmonary thromboemboslism - ROL of CT and SPECT in the PTE

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007999

Enrollment

Registered

2012-06-01

Start date

2012-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary thromboembolism

Interventions

CT pulmonary agngiography CT venography lung perfusin SPECT

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed as acute pulmonary thromboembolism with CT paulmonary angiographt

Exclusion criteria

Exclusion criteria: Past history of pulmonary thromboembolsim

Design outcomes

Primary

Measure	Time frame
Transition of acute pulmonary thromboembolism to chronic thromboembolic pulmonary hypertension	—

Secondary

Measure	Time frame
Findings of CT pulmonary angiography and SPECT RV dimension, RV dyssynergy and estimated PA pressure on cardica US	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026